Fujitsu and Tokyo Medical and Dental University have installed a technology that presents new discoveries from field data developed by Fujitsu on the supercomputer "Tomitake" and extracted the causal mechanism of genes that suggest the cause of resistance to lung cancer therapeutic drugs. I succeeded in doing it.Fujitsu believes that the use of this technology can be expected to develop effective anti-cancer drugs for each patient.
According to Fujitsu, the new technology uses AI (artificial intelligence) technology that can explain the basis of judgment and discover knowledge, and comprehensively extracts conditions with characteristic causal relationships, and is named "AI to discover". Was done.However, when a comprehensive search was conducted on all 2 human genes, it was estimated that it would take more than 4,000 years with a normal computer, and speeding up the processing was an issue.
Therefore, Fujitsu and others parallelized algorithms for conditional search and causal search so that all human genes could be analyzed in a practical time, and implemented them in Tomitake. It has become possible to find unknown causes and effects.As a result of searching for the cause and effect based on the public data, we succeeded in identifying the gene that suggests that it causes resistance to the lung cancer drug "gefitinib".
Professor Seiji Ogawa of the Graduate School of Medicine, Kyoto University said, "The key to successful new drug development is to find patients who can be expected to be effective and conduct clinical trials. This new technology is likely to be a force to promote it, and pharmaceutical companies are interested. You can expect to have it. "
